{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:27:21Z","timestamp":1791638841666,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ameloblastoma is a rare odontogenic neoplasm frequently located in the mandible. Standard treatment involves radical bone resection and immediate reconstruction, causing functional, aesthetic, and psychological impairments. The BRAF V600E mutation is present in approximately 80% of mandible ameloblastomas, and BRAF inhibitors have demonstrated sustained responses in unresectable cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified ameloblastoma patients planned for ablative surgery and screened them for BRAF V600E mutation. Neoadjuvant BRAF inhibitors were offered to facilitate jaw preservation surgery. Retrospective data collection encompassed treatment regimens, tolerability, tumor response, and conversion to mandible preservation surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2017 and 2022, a total of 11 patients received dabrafenib (n\u2009=\u20096) or dabrafenib with trametinib (n\u2009=\u20095). The median age was 19 (range = 10-83) years. Median treatment duration was 10 (range = 3-20) months. All (100%) patients achieved a radiological response. Ten (91%) patients successfully converted to mandible preservation surgery with residual tumor enucleation. One patient attained complete radiological response, and surgery was not performed. Among the 10 surgically treated patients, all exhibited a pathological response, with 4 achieving near complete response and 6 partial response. At a median follow-up of 14 (range = 7-37) months after surgery, 1 case of recurrence was observed. Grade 1-2 adverse effects were reported in 8 (73%) patients, with a single case of grade 3 (hepatitis). Dose modification was necessary for 3 patients, and 4 experienced treatment interruptions, while 1 patient permanently discontinued therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant BRAF inhibition may offer a safe and effective strategy for organ preservation in mandible ameloblastoma treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djad232","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:17:10Z","timestamp":1699964230000},"page":"539-546","source":"Crossref","is-referenced-by-count":39,"title":["Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach"],"prefix":"10.1093","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-2100","authenticated-orcid":false,"given":"Shirly","family":"Grynberg","sequence":"first","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1187-2333","authenticated-orcid":false,"given":"Marilena","family":"Vered","sequence":"additional","affiliation":[{"name":"Institue of Pathology, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-080X","authenticated-orcid":false,"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4094-8045","authenticated-orcid":false,"given":"Nethanel","family":"Asher","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-4469","authenticated-orcid":false,"given":"Guy","family":"Ben-Betzalel","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-9148","authenticated-orcid":false,"given":"Ronen","family":"Stoff","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-5062","authenticated-orcid":false,"given":"Yael","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-6718","authenticated-orcid":false,"given":"Ninette","family":"Amariglio","sequence":"additional","affiliation":[{"name":"Sheba Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-9363","authenticated-orcid":false,"given":"Gahl","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-8963","authenticated-orcid":false,"given":"Iris","family":"Barshack","sequence":"additional","affiliation":[{"name":"Institue of Pathology, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-8869","authenticated-orcid":false,"given":"Amos","family":"Toren","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Yahalom","sequence":"additional","affiliation":[{"name":"Department of Cranio-Maxillofacial Surgery, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4550-6481","authenticated-orcid":false,"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Rechavi","sequence":"additional","affiliation":[{"name":"Sheba Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Hirschhorn","sequence":"additional","affiliation":[{"name":"Department of Cranio-Maxillofacial Surgery, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-8081","authenticated-orcid":false,"given":"Gadi","family":"Abebe Campino","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center , Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"3","key":"2024040509034498400_djad232-B1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/1097-0142(197009)26:3<699::AID-CNCR2820260331>3.0.CO;2-K","article-title":"Ameloblastoma: delineation of early histopathologic features of neoplasia","volume":"26","author":"Vickers","year":"1970","journal-title":"Cancer"},{"issue":"6","key":"2024040509034498400_djad232-B2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/COC.0b013e3181573e59","article-title":"Ameloblastoma","volume":"30","author":"Mendenhall","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"2024040509034498400_djad232-B3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/odi.12646","article-title":"Ameloblastoma: Current etiopathological concepts and management","volume":"24","author":"Effiom","year":"2018","journal-title":"Oral Dis"},{"issue":"2","key":"2024040509034498400_djad232-B4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0030-4220(84)90207-X","article-title":"Malignant ameloblastoma or ameloblastic carcinoma","volume":"57","author":"Slootweg","year":"1984","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"1","key":"2024040509034498400_djad232-B5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13023-020-01603-5","article-title":"Study on clinical and biological characteristics of ameloblastic carcinoma","volume":"15","author":"Niu","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2024040509034498400_djad232-B6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.surge.2020.06.009","article-title":"Ameloblastoma: a succinct review of the classification, genetic understanding and novel molecular targeted therapies","volume":"19","author":"Shi","year":"2021","journal-title":"Surgeon"},{"issue":"1","key":"2024040509034498400_djad232-B7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s42047-019-0041-z","article-title":"Ameloblastomas: current aspects of the new WHO classification in an analysis of 136 cases","volume":"2","author":"Cadavid","year":"2019","journal-title":"Surg Exp Pathol"},{"issue":"7","key":"2024040509034498400_djad232-B8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00405-015-3631-8","article-title":"Ameloblastoma: a clinical review and trends in management","volume":"273","author":"McClary","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"2024040509034498400_djad232-B9","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/odi.13014","article-title":"Radical vs conservative treatment of intraosseous ameloblastoma: systematic review and meta-analysis","volume":"25","author":"Hendra","year":"2019","journal-title":"Oral Dis"},{"issue":"1","key":"2024040509034498400_djad232-B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0975-5950.85849","article-title":"Surgical management of ameloblastoma: conservative or radical approach","volume":"2","author":"Dandriyal","year":"2011","journal-title":"Natl J Maxillofac Surg"},{"issue":"4","key":"2024040509034498400_djad232-B11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/SAP.0b013e3182a0dedf","article-title":"Aesthetic and functional mandibular reconstruction with immediate dental implants in a free fibular flap and a low-profile reconstruction plate: five-year follow-up","volume":"74","author":"Shen","year":"2015","journal-title":"Ann Plast Surg"},{"issue":"4","key":"2024040509034498400_djad232-B12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijom.2006.11.003","article-title":"Long-term follow up on recurrence of 305 ameloblastoma cases","volume":"36","author":"Hong","year":"2007","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"5","key":"2024040509034498400_djad232-B13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5999\/aps.2018.01487","article-title":"A 20-year experience of immediate mandibular reconstruction using free fibula osteocutaneous flaps following ameloblastoma resection: radical resection, outcomes, and recurrence","volume":"46","author":"Chai","year":"2019","journal-title":"Arch Plast Surg"},{"issue":"1","key":"2024040509034498400_djad232-B14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coms.2015.08.003","article-title":"Pediatric odontogenic tumors","volume":"28","author":"Abrahams","year":"2016","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"1","key":"2024040509034498400_djad232-B15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/SCS.0000000000005840","article-title":"Tissue engineering and regenerative medicine in craniofacial reconstruction and facial aesthetics","volume":"31","author":"Borrelli","year":"2020","journal-title":"J Craniofac Surg"},{"issue":"1","key":"2024040509034498400_djad232-B16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/23320885.2021.1886854","article-title":"Ameloblastoma: clinical presentation, multidisciplinary management and outcome","volume":"8","author":"Medina","year":"2021","journal-title":"Case Rep Plast Surg Hand Surg"},{"key":"2024040509034498400_djad232-B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-030-24100-1_2","article-title":"Next Generation Sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer","volume":"1168","author":"Morganti","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2024040509034498400_djad232-B18","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2024040509034498400_djad232-B19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0022034518798810","article-title":"The mutational profile of unicystic ameloblastoma","volume":"98","author":"Heikinheimo","year":"2019","journal-title":"J Dent Res"},{"issue":"21","key":"2024040509034498400_djad232-B20","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1158\/1078-0432.CCR-14-1069","article-title":"Activating FGFR2\u2013RAS\u2013BRAF mutations in ameloblastoma","volume":"20","author":"Brown","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024040509034498400_djad232-B21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bcp.2010.03.019","article-title":"BRAF as therapeutic target in melanoma","volume":"80","author":"Wellbrock","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"2024040509034498400_djad232-B22","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/1078-0432.CCR-20-1024","article-title":"Population-based screening for BRAFV600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis","volume":"26","author":"Chu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2024040509034498400_djad232-B23","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024040509034498400_djad232-B24","first-page":"548","article-title":"BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov."},{"issue":"33","key":"2024040509034498400_djad232-B25","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"2024040509034498400_djad232-B26","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2024040509034498400_djad232-B27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2024040509034498400_djad232-B28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024040509034498400_djad232-B29","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"2024040509034498400_djad232-B30","author":"U.S. Food and Drug Administration","year":"2022"},{"issue":"2","key":"2024040509034498400_djad232-B31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CCO.0000000000000050","article-title":"The role of MEK inhibitors in the treatment of metastatic melanoma","volume":"26","author":"Grimaldi","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"2024040509034498400_djad232-B32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.oooo.2016.05.017","article-title":"BRAF inhibitor therapy of primary ameloblastoma","volume":"122","author":"Tan","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"2024040509034498400_djad232-B33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/jnci\/dju378","article-title":"Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma","volume":"107","author":"Kaye","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2024040509034498400_djad232-B34","doi-asserted-by":"crossref","first-page":"djw190","DOI":"10.1093\/jnci\/djw190","article-title":"Durable treatment of ameloblastoma with single agent BRAFi Re: clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma","volume":"109","author":"Faden","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2024040509034498400_djad232-B35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1186\/s12885-018-4802-y","article-title":"Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation","volume":"18","author":"Fernandes","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"2024040509034498400_djad232-B36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13256-019-2140-6","article-title":"Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report","volume":"13","author":"Broudic-Guibert","year":"2019","journal-title":"J Med Case Rep"},{"issue":"12","key":"2024040509034498400_djad232-B37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/term.3254","article-title":"Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration","volume":"15","author":"Hirschhorn","year":"2021","journal-title":"J Tissue Eng Regen Med"},{"issue":"8","key":"2024040509034498400_djad232-B38","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/1097-0142(19840415)53:8<1730::AID-CNCR2820530819>3.0.CO;2-U","article-title":"Plexiform unicystic ameloblastoma. A variant of ameloblastoma with a low-recurrence rate after enucleation","volume":"53","author":"Gardner","year":"1984","journal-title":"Cancer"},{"issue":"19","key":"2024040509034498400_djad232-B39","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djad232\/54770400\/djad232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/4\/539\/57164434\/djad232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/4\/539\/57164434\/djad232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T05:59:04Z","timestamp":1712296744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/116\/4\/539\/7421919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,15]]},"published-print":{"date-parts":[[2024,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djad232","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2023,11,15]]}}}